… This includes either direct inhibition of viral replication by targeting fundamental steps … potent
NAs, drug development could be improved by focusing on polymerase inhibitors that target …

Hepatitis B virus (HBV) infection affects approximately 300 million people worldwide. Although
antiviral therapies have improved the long-term outcomes, patients often require life-long …

… Only by targeting novel molecular mechanisms of the virus and infected cells at various …
SiRNA may be one of the most powerful agents that may lead to sustained viral suppression if …

… If 100% effective, replication inhibitors themselves should prevent de novo infection and
offer an alternative to specifically targeting the HBsAg–NTCP interaction. In this strategy, …

… Chronic hepatitis B (CHB) virus infection is a significant public health problem and causes
… The CHB current treatment with a potent and a high genetic barrier NA (ETV, TDF, and TAF) …

… Hepatitis B virus (HBV) infection is a major cause of chronic liver … While de novo infection
can be efficiently prevented by … of acutely infected adults resolve HBV infection via strong and …

… hepatitis [43] and (2) HBV eradication [76]. Based on the fact that NK cells play important roles
in immune responses against viral infections … approaches against hepatitis B infection and …

… cholesterol-conjugated siRNA (chol-siRNA) targeting coagulation factor VII (F7) results in …
infection, we show that a single coinjection of NAG-MLP with potent chol-siRNAs targeting …

… Globally, hepatitis B virus (HBV) and hepatitis C virus (HCV) … (1, 2) Viral hepatitis due to
chronic HBV and HCV infection leads … -infected individuals are co-infected with the hepatitis delta …

… , but we expect a potent synergistic effect on patients with … of viral replication, the viral antigen
is difficult to target using … Toll-like receptors (TLRs) are the initial sensors of viral infection …